SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SYRE SPYRE THERAPEUTICS INC

交易中 04-30 14:59:41 EDT

74.24

+2.35

+3.27%

最高75.00	最低72.08	成交量54.08万
今开72.33	昨收71.89	日振幅4.06%
总市值64.04亿	流通市值53.86亿	总股本8,626万
成交额4,003万	换手率0.75%	流通股本7,255万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":74.24,"timestamp":1777575577689,"preClose":71.89,"halted":0,"volume":540787,"delay":0,"changeRate":0.03268883015718451,"floatShares":72553500,"shares":86259400,"eps":-1.98,"marketStatus":"交易中","change":2.35,"latestTime":"04-30 14:59:41 EDT","open":72.33,"high":74.9999,"low":72.08,"amount":40030995.16533,"amplitude":0.040616,"askPrice":74.33,"askSize":44,"bidPrice":74.17,"bidSize":42,"shortable":3,"etf":0,"ttmEps":-1.98,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1777579200000},"marketStatusCode":2,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":71.89,"preHourTrading":{"tag":"盘前","latestPrice":72.28,"preClose":71.89,"latestTime":"09:29 EDT","volume":907,"amount":65438.145300000004,"timestamp":1777555799999,"change":0.39,"changeRate":0.005425,"amplitude":0.02782},"postHourTrading":{"tag":"盘后","latestPrice":71.9,"preClose":71.89,"latestTime":"19:36 EDT","volume":119231,"amount":8571570.49,"timestamp":1777505774714,"change":0.01,"changeRate":0.000139,"amplitude":0.000139},"volumeRatio":0.657435,"impliedVol":0.6941,"impliedVolPercentile":0.494},"requestUrl":"/m/hq/s/SYRE","defaultTab":"news","newsList":[{"id":"1120556014","title":"异动解读 | Spyre Therapeutics获强力买入评级，盘前大涨6.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120556014","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120556014?lang=zh_cn&edition=full","pubTime":"2026-04-14 21:31","pubTimestamp":1776173485,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc（SYRE）今日盘前股价大涨6.99%，引起了市场的关注。消息面上，Raymond James分析师马丁・奥斯特首次覆盖Spyre Therapeutics，并给予其“强力买入”评级，目标价设定为80美元。该目标价显著高于公司股票周一63.27美元的收盘价，这向市场传递了积极的信号，增强了投资者对公司未来股价表现的信心，从而推动了股价在盘前交易中上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627469264","title":"【券商聚焦】华尔街顶尖分析师调整闪迪等多家企业评级展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2627469264","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627469264?lang=zh_cn&edition=full","pubTime":"2026-04-14 20:12","pubTimestamp":1776168740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华尔街头部分析师近期陆续更新多家热门上市公司的投资评级与目标价：Evercore ISI分析师阿米特达里亚尼首次覆盖闪迪 ，给予其跑赢大盘评级，设定目标价 1200 美元。摩根士丹利分析师罗纳德坎德姆首次覆盖Janus Living，给出增持评级，目标价定为 28 美元。Evercore ISI 分析师彼得莱文首次覆盖边缘云服务商Fastly，评级为跑赢大盘，目标价 32 美元，该股周一收盘价 24.37 美元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/ZWQyMzQ4MWViNTBlNjYyZWIyNzg3MGMyMTYyODU5MDY5NTc1OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZWQyMzQ4MWViNTBlNjYyZWIyNzg3MGMyMTYyODU5MDY5NTc1OQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299168","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNXX","BK4613","SYRE","BK4554","LU0054578231.USD","FSLY","LU0963586101.USD","BK4139","BK4116","BK4225","BK4608","JAN","SNDK","BK4120","BK4007","BK4170","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104189294","title":"Spyre Therapeutics公司宣布暂停并终止ATM发行招股说明书 2026年4月13日正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1104189294","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104189294?lang=zh_cn&edition=full","pubTime":"2026-04-14 04:31","pubTimestamp":1776112280,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会的文件显示，生物制药公司Spyre Therapeutics Inc已决定暂停并终止其在场内发行计划相关的招股说明书。该决定将于2026年4月13日正式生效。这意味着Spyre Therapeutics公司将不再通过ATM发行方式出售普通股。ATM发行是一种灵活的融资方式，允许上市公司在需要时通过经纪商在公开市场上逐步出售股票。暂停和终止ATM招股说明书的举措，通常意味着公司短期内不会通过该渠道进行股权融资。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627458246","title":"Spyre盘前股价上涨23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627458246","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627458246?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:47","pubTimestamp":1776080820,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月13日，Spyre盘前股价上涨23%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-04-13/doc-inhukeex9689769.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-13/doc-inhukeex9689769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SYRE","BK4023","BK4588","LU1852331112.SGD","IE00B894F039.SGD","BK4613","BK4587","BK4585","BK4528","LU1861215975.USD","BK4608","LU0097036916.USD","LU0353189763.USD","LU2063271972.USD","LU2087625088.SGD","LU0353189680.USD","BK4539","LU2290526834.HKD","LU2360106780.USD","AIYY","APPX","IE00BZ9MQY76.HKD","BK4543","LU2250418816.HKD","LU2360107168.USD","LU1861220033.SGD","LU0056508442.USD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188201235","title":"SPYRE THERAPEUTICS INC股价盘前飙升23% 公司宣布炎症性肠病药物中期研究显示疾病活动度降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1188201235","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188201235?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:46","pubTimestamp":1776080778,"startTime":"0","endTime":"0","summary":"SPYRE THERAPEUTICS INC股价在盘前交易中大幅上涨23%，此前该公司宣布其针对炎症性肠病的药物在一项中期研究中显示出能够显著降低疾病活动度。\n这一积极的研究结果提振了投资者信心，推动该公司股价在开盘前即迎来强劲涨势。该药物在临床试验中达到主要终点，为患有此类慢性肠道疾病的患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191160307","title":"Spyre公布Skyline试验中重度溃疡性结肠患者Spy001 Part a诱导期潜在最佳疗效数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1191160307","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191160307?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:09","pubTimestamp":1776078591,"startTime":"0","endTime":"0","summary":"生物制药公司Spyre Therapeutics公布了其Skyline临床试验中针对中重度溃疡性结肠炎患者的Spy001 Part a诱导期研究结果，数据显示该疗法可能具备同类最优潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197836690","title":"Spyre Therapeutics：诱导治疗期间六名受试者出现治疗突发不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1197836690","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197836690?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:00","pubTimestamp":1776078043,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司在诱导治疗阶段报告了六例治疗相关不良事件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175357309","title":"Spyre Therapeutics药物Spy001达成主要终点：RHI评分显著降低9.2分，统计学差异凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=1175357309","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175357309?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:00","pubTimestamp":1776078031,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc宣布，其候选药物Spy001在临床试验中成功达成主要研究终点。数据显示，该药物使RHI评分出现具有统计学意义的显著下降，降幅达到9.2分。这一积极结果标志着项目取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152663853","title":"Spyre Therapeutics次要终点数据亮眼：改良Mayo评分临床缓解率达40%，内镜改善率51%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152663853","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152663853?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:00","pubTimestamp":1776078015,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司最新研究数据显示，其次要疗效终点取得显著成果。根据改良Mayo评分标准，患者临床缓解率达到40%，同时内镜下黏膜改善率表现更为突出，达到51%的水平。\n该数据反映了候选疗法在炎症性肠病治疗领域的潜在价值，两项关键指标共同印证了治疗方案的临床有效性。值得注意的是，内镜改善率超过临床缓解率11个百分点，提示该疗法可能对黏膜愈合具有特别优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129097336","title":"Spyre Therapeutics公布Spy001二期Skyline试验A部分12周诱导期积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1129097336","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129097336?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:00","pubTimestamp":1776078011,"startTime":"0","endTime":"0","summary":"生物制药公司Spyre Therapeutics近日宣布，其在研药物Spy001于二期临床试验Skyline的A部分取得了积极的12周诱导期数据。这项进展为后续研究奠定了良好基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148597267","title":"Spyre Therapeutics宣布Skyway类风湿性关节炎亚组研究顶线结果预期提前至2026年第三季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1148597267","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148597267?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:35","pubTimestamp":1773664501,"startTime":"0","endTime":"0","summary":"生物制药公司Spyre Therapeutics最新公告显示，其针对类风湿性关节炎的Skyway研究项目亚组分析顶线结果揭晓时间将较原计划提前。该关键数据发布节点现已调整为2026年第三季度。\n此次时间表优化源于临床研究进程的显著提速，预示着公司在该疾病领域的研发效率获得实质性突破。作为自身免疫疾病治疗领域的重要进展，这项亚组研究结果的提前披露将为药物疗效评估提供更早的决策依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177535994","title":"Spyre Therapeutics - Spy003显示约85天的半衰期，支持每季度或每年两次的维持剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1177535994","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177535994?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:40","pubTimestamp":1762292412,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics - Spy003显示约85天的半衰期，支持每季度或每年两次的维持剂量","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173012956","title":"Spyre Therapeutics：Spy003在所有剂量水平上耐受良好，安全性特征符合抗IL-23类药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1173012956","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173012956?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:40","pubTimestamp":1762292408,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics：Spy003在所有剂量水平上耐受良好，安全性特征符合抗IL-23类药物","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132251468","title":"Spyre Therapeutics发布Spy003的积极中期I期结果，这是一种新型半衰期延长的抗IL-23抗体","url":"https://stock-news.laohu8.com/highlight/detail?id=1132251468","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132251468?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:02","pubTimestamp":1762290128,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics发布Spy003的积极中期I期结果，这是一种新型半衰期延长的抗IL-23抗体","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518327167","title":"Spyre Therapeutics, Inc.盘中异动 早盘股价大跌5.21%报18.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518327167","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518327167?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:36","pubTimestamp":1741617373,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时36分，Spyre Therapeutics, Inc.股票出现波动，股价大幅跳水5.21%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223613abf314b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223613abf314b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518440864","title":"Spyre Therapeutics, Inc.2024财年实现净利润-1.50亿美元，同比减少58.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440864","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518440864?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449622,"startTime":"0","endTime":"0","summary":"3月9日，Spyre Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.50亿美元，同比减少58.09%；其中营业收入为0.00美元，每股基本收益为-3.18美元。从资产负债表来看，Spyre Therapeutics, Inc.总负债90.68百万美元，其中短期债务0.00美元，资产负债比为0.07，流动比率为0.12。机构评级：截至2025年3月9日，当前有8家机构对Spyre Therapeutics, Inc.目标价做出预测，其中目标均价为58.62美元，其中最低目标价为40.00美元，最高目标价为71.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000037abef96fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000037abef96fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196051233","title":"异动解读 | Spyre Therapeutics Inc盘中大涨6.97%,新药研发取得重大进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1196051233","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196051233?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:08","pubTimestamp":1741187300,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc作为一家专注于新型肠病药物研发的生物技术公司,周三盘中出现了6.97%的大涨行情,引发了市场的广泛关注。分析人士指出,SYRE股价大涨的原因可能与该公司最新研发进展有关。SYRE的这款新药主打免疫调节作用,与现有主流药物采用不同的治疗机理,预计上市后将给这一疾病领域带来全新的治疗选择。随着临床数据的持续披露,投资者对新药未来前景的信心不断增强,这也是推动SYRE股价持续走高的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Spyre Therapeutics Inc盘中大涨6.97%,新药研发取得重大进展","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517943943","title":"Spyre Therapeutics, Inc.盘中异动 股价大涨6.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517943943","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517943943?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:32","pubTimestamp":1741185121,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时32分，Spyre Therapeutics, Inc.股票出现异动，股价快速拉升6.97%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223201963adc60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223201963adc60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514781803","title":"Spyre Therapeutics, Inc.盘中异动 早盘快速上涨8.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514781803","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514781803?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753076,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Spyre Therapeutics, Inc.股票出现波动，股价快速拉升8.74%。Spyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Spyre Therapeutics, Inc.公司简介：Spyre Therapeutics Inc 是一家生物技术公司，旨在通过结合抗体工程，合理的治疗组合和精确的医学方法来为患者选择，创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223116a25800d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223116a25800d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514516354","title":"Spyre Therapeutics(SYRE.US)：2024年Q4财报实现营收0美元，前值为0美元，预期值为233万美元；每股收益为-0.81美元，前值为-4.05美元，预期值为-0.97美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514516354","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514516354?lang=zh_cn&edition=full","pubTime":"2025-02-28 07:08","pubTimestamp":1740697720,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics(SYRE.US)：2024年Q4财报实现营收0美元，前值为0美元，预期值为233万美元；每股收益为-0.81美元，前值为-4.05美元，预期值为-0.97美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28070848442547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SYRE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.spyre.com","stockEarnings":[{"period":"1week","weight":-0.0152},{"period":"1month","weight":0.5828},{"period":"3month","weight":1.1409},{"period":"6month","weight":1.9391},{"period":"1year","weight":3.7863},{"period":"ytd","weight":1.1944}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Spyre Therapeutics, Inc.于2013年12月16日从特拉华州有限责任公司转换而来。该公司是一家生物技术公司，旨在通过结合同类最佳的抗体工程、合理的治疗组合以及用于患者选择的精准医疗方法，创造下一代炎症性肠病（IBD）产品。Spyre的产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.035303},{"month":2,"riseRate":0.5,"avgChangeRate":0.028912},{"month":3,"riseRate":0.5,"avgChangeRate":0.022238},{"month":4,"riseRate":0.2,"avgChangeRate":-0.01503},{"month":5,"riseRate":0.5,"avgChangeRate":-0.058711},{"month":6,"riseRate":0.4,"avgChangeRate":0.119173},{"month":7,"riseRate":0.4,"avgChangeRate":-0.002229},{"month":8,"riseRate":0.8,"avgChangeRate":0.108946},{"month":9,"riseRate":0.6,"avgChangeRate":0.016514},{"month":10,"riseRate":0.4,"avgChangeRate":0.109394},{"month":11,"riseRate":0.4,"avgChangeRate":0.005048},{"month":12,"riseRate":0.4,"avgChangeRate":-0.019416}],"exchange":"NASDAQ","name":"SPYRE THERAPEUTICS INC","nameEN":"SPYRE THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供SPYRE THERAPEUTICS INC(SYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"SPYRE THERAPEUTICS INC,SYRE,SPYRE THERAPEUTICS INC股票,SPYRE THERAPEUTICS INC股票老虎,SPYRE THERAPEUTICS INC股票老虎国际,SPYRE THERAPEUTICS INC行情,SPYRE THERAPEUTICS INC股票行情,SPYRE THERAPEUTICS INC股价,SPYRE THERAPEUTICS INC股市,SPYRE THERAPEUTICS INC股票价格,SPYRE THERAPEUTICS INC股票交易,SPYRE THERAPEUTICS INC股票购买,SPYRE THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供SPYRE THERAPEUTICS INC(SYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}